Medtronic (NYSE:MDT) was upgraded by Argus from a “hold” rating to a “buy” rating in a research report issued on Tuesday, The Fly reports. The analysts noted that the move was a valuation call.

Several other research analysts also recently commented on MDT. Royal Bank of Canada reissued a “buy” rating and issued a $90.00 price objective on shares of Medtronic in a research note on Monday, August 21st. Oppenheimer restated a “buy” rating and issued a $92.00 target price on shares of Medtronic in a report on Tuesday, August 22nd. Cowen set a $95.00 target price on Medtronic and gave the company a “buy” rating in a report on Tuesday, August 22nd. BMO Capital Markets restated an “outperform” rating and issued a $92.00 target price (down from $94.00) on shares of Medtronic in a report on Wednesday, August 23rd. Finally, Barclays dropped their target price on Medtronic from $94.00 to $92.00 and set an “overweight” rating for the company in a report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $88.26.

Medtronic (NYSE:MDT) opened at $81.27 on Tuesday. Medtronic has a 52 week low of $69.35 and a 52 week high of $89.72. The company has a quick ratio of 2.05, a current ratio of 2.40 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $109,728.08, a price-to-earnings ratio of 17.47, a P/E/G ratio of 2.24 and a beta of 1.00.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.08. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The firm had revenue of $7.05 billion during the quarter, compared to the consensus estimate of $7.05 billion. During the same period in the prior year, the company earned $1.12 EPS. The firm’s revenue was down 4.0% compared to the same quarter last year. equities analysts predict that Medtronic will post 4.77 earnings per share for the current year.

In other Medtronic news, CEO Omar Ishrak sold 140,407 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $81.63, for a total value of $11,461,423.41. Following the sale, the chief executive officer now owns 668,503 shares of the company’s stock, valued at approximately $54,569,899.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Bryan C. Hanson sold 16,000 shares of the stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $78.03, for a total value of $1,248,480.00. The disclosure for this sale can be found here. Insiders have sold a total of 172,407 shares of company stock valued at $13,974,223 over the last 90 days. 0.31% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of MDT. Hudock Capital Group LLC grew its stake in shares of Medtronic by 0.5% in the 2nd quarter. Hudock Capital Group LLC now owns 2,195 shares of the medical technology company’s stock valued at $194,000 after purchasing an additional 11 shares during the last quarter. Triangle Securities Wealth Management boosted its stake in shares of Medtronic by 0.3% in the second quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock valued at $390,000 after buying an additional 15 shares in the last quarter. IFC Holdings Incorporated FL boosted its stake in shares of Medtronic by 0.3% in the second quarter. IFC Holdings Incorporated FL now owns 5,673 shares of the medical technology company’s stock valued at $501,000 after buying an additional 17 shares in the last quarter. Arcus Capital Partners LLC boosted its stake in shares of Medtronic by 0.8% in the second quarter. Arcus Capital Partners LLC now owns 3,249 shares of the medical technology company’s stock valued at $288,000 after buying an additional 25 shares in the last quarter. Finally, Guardian Life Insurance Co. of America boosted its stake in shares of Medtronic by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 5,288 shares of the medical technology company’s stock valued at $426,000 after buying an additional 29 shares in the last quarter. 81.86% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Medtronic (MDT) Upgraded at Argus” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/12/medtronic-mdt-upgraded-at-argus.html.

Medtronic Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

The Fly

Analyst Recommendations for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.